Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.
Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma
Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.
Optimizing Frailty Tools Are A Vital Component of Improving Care Across Hematologic Malignancies
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.
Noncovalent BTK Inhibitors May Fill Unmet Needs in CLL and Other Top ASH Takeaways
Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.
Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma
Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Mosunetuzumab Shows High Response Rates in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab, an off-the-shelf outpatient therapy with a fixed duration of treatment, demonstrated promising responses in patients with relapsed/refractory follicular lymphoma.
Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis
Aaron T. Gerds, MD, MS, unpacks data seen with momelotinib for patients with anemic myelofibrosis.
Pirtobrutinib Displays High Response Rate in Pretreated Waldenström Macroglobulinemia
Heavily pretreated patients with Waldenström macroglobulinemia demonstrated encouraging responses with pirtobrutinib, a non-covalent BTK inhibitor.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL
Blinatumomab plus consolidation chemotherapy demonstrated a survival advantage for patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
TKIs Do Not Add Protective Benefit Against Peripheral Neuropathy in Patients With ALL Receiving Vincristine
Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.
Phase 3 Data Support Leaving the “Neutrodiet” Behind After Stem Cell Transplant
A nonrestrictive diet was found to be noninferior to a protective diet in the post-stem cell transplant setting, suggesting that lifting restrictions may improve patient quality of life.
Real-World Patient-Reported Outcomes for Axi-Cel Align With Clinical Trial QOL, Symptomology Data
Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.
Daratumumab-Quadruplet Therapy Yields Promising HRQOL Scores in Transplant Eligible, Newly Diagnosed, Multiple Myeloma
Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.
Monitoring Amphiregulin May Be Warranted in Caring for Patients with Acute GVHD
Patients with high levels of amphiregulin were at a higher risk of an early death in acute graft-versus-host-disease, according to a presentation at the 2021 ASH Annual Meeting.
Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Appears Safe in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin is an antibody-drug conjugate that functions by targeting BCMA and has demonstrated clinically meaningful activity in relapsed/refractory multiple myeloma.
Patients with LBCL Experience Improved Quality of Life Following Axi-Cel Treatment
Axicabtagene ciloleucel improved the quality of life in patients with relapsed/refractory large B-cell lymphoma receiving the agent as a second-line therapy.
Real-World Data Supports Clinical Benefit of Tisagenlecleucel in Relapsed/Refractory B-Cell ALL
Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.
Cilta-cel May Be Superior Therapy in Triple-Class Relapsed/Refractory Myeloma
In comparison to physicians’ choice of treatment, ciltacabtagene autoleucel demonstrated significant advantages in progression-free and overall survival, time to next treatment, and overall response rate.
R-Mini-Chop Plus Ibrutinib Extends Progression-Free Survival in Elderly Patients With Newly Diagnosed DLBCL
Combining ibrutinib with rituximab resulted in improved 2-year progression-free survival among elderly patients with previously untreated diffuse large B-cell lymphoma.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive Cranbury, NJ 08512